BIIB Related Analyst EPS View
-
Biogen (BIIB) Might Buy Remaining Interest in Tysabri from Elan (ELN)
-
UPDATE: Citi Downgrades Biogen (BIIB) to Neutral
-
Biogen's (BIIB) BG-12 Data Not Inflated
-
Biogen (BIIB) Weeks-6 TECFIDERA Scripts Continue to Ramp
-
Biogen's (BIIB) TECFIDERA Scripts Accelerating WoW
-
Scripts Data Indicates Biogen's (BIIB) Tecfidera Could Beat 2013 Estimates by $400M
-
Goldman Sachs Upgrades Amgen (AMGN) to Conviction Buy
-
Deutsche Bank Sees Upside for Biogen's (BIIB) Tecfidera
-
Jefferies Lifts Numbers on Biogen (BIIB) Post Q1
-
Deutsche Bank Maintains Buy on Biogen (BIIB)
-
Deutsche Bank Raises Biogen (BIIB) Price Target to $240
-
Strong Biogen (BIIB) Tecfideara Sales Tied to Patient 'Warehousing'
-
Early Data Says Biogen's (BIIB) Tecfidera Doing Well - Analyst
-
What Next for Biogen (BIIB)? Anlaysts Weigh In
-
UPDATE: UBS Downgrades Biogen (BIIB) to Neutral; Risk/Reward Now Balanced
-
UBS Maintains a 'Buy' on Biogen (BIIB); Key Takeaways from 2Q12
-
Jefferies Maintains a 'Buy' on Biogen (BIIB) on Strong Q2; Adjusting Numbers
-
Q2 Kickoff: Alcoa (AA) Investors to Focus on LME Prices, Downstream Ops, and China
-
UBS Maintains a 'Buy' on Biogen (BIIB); Core Franchise Support Valuation; Pipeline Provides Upside Risk
-
Baird Maintains a 'Neutral' on Biogen (BIIB); Still Prefer the Sidelines as Pipeline Remains The Focus
-
Baird Maintains a 'Neutral' on Biogen (NASDAQ: BIIB); Raising Estimates Ahead of Earnings
Back to BIIB Stock Lookup
